Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Count me in
Close contact with asymptomatic wife covid 19 positive while on vacation
I remain negative
They need ton launch first then
1) figure out how to prove infringement
2) examine their pill and see if they infringe on other manifacturing Amarin’s patents.
Sure
Above 500 anywhere from 0 to 2 scripts
Reduce it criteria. Maybe 60 to 80 per month.
So that would be one way to prove infringement?
Not sure if this is currently airing
I agree
But don’t sue doctors. Nothing to do with the switch
Sue insurances. Nothing to lose except for legal fees.
Problem with this case is that apotex changed the dosing so this case may not help.
No, they don’t.
There are companies like symphony
They count every script.
We get counts and market percent held for each GEneric lovaza, generic vascepa and Vascepa. This is not rocket science.
We know Marine patients are very rare.
Sue generics because their sales numbers will prove infringement, and they cannot play stupid.
Marine population 1.2 percent.
In my practice maybe 5 to 10 patients out of 2000
In the United States, the National Health and Nutrition Examination Surveys from 2007 to 2014 found that the percentages of non-statin-treated adults with triglyceride levels >150 mg/dL (1.7 mmol/L), >200 mg/dL (2.3 mmol/L), >500 mg/dL (5.7 mmol/L), and >1000 mg/dL (11.3 mmol/L) were 25, 11, 1, and <1 percent, respectively [2]. There were also racial and ethnic differences, with non-Hispanic African Americans having lower fasting TG levels than in non-Hispanic Caucasians and Mexican Americans [3].
Serum TG values >1000 mg/dL (11.3 mmol/L) occur in fewer than 1 in 5000 individuals [4].
So if they sell more than expected they are infringing Reduce It patents.
Can you find out how many awarded after rule 36?
I have more chance in winning the power-ball than Amarin getting this through the legal system.
They should look how to enforce their Reduce-it patents. Sue generics. Sue the insurances. Whatever.
Amarin reps are panicking. Many are looking for new jobs. Amarin told them everything stays the same as before. No layoffs.
Not sure but i know they should file a lawsuit in Alabama:)
If you read the article Astra Zeneca already won against Apotex. The judge said Apotex cannot take more than 5 percent of the market without infringement
https://www.fr.com/files/uploads/attachments/Skinny_Labeling_Inducement_of_Patent_Infringement_Nov-Dec-2010.pdf
I feel this is our best chance.
Marine population prevalence is 1.1 percent. The article is from the UPTODATE. 1.1 percent. That’s it.
They cannot take 50 percent market and say they are not infringing.
We still have REDUCE IT patent intact.
https://www.fr.com/files/uploads/attachments/Skinny_Labeling_Inducement_of_Patent_Infringement_Nov-Dec-2010.pdf
Trig above 500 prevalence is little bit more than 1 percent.
So amarin can easily prove infringement
. PREVALENCE
Hypertriglyceridemia is common in clinical practice, with a prevalence of about 10 percent, depending on the population being studied. In individuals with established cardiovascular disease, the prevalence will be higher [1].
In the United States, the National Health and Nutrition Examination Surveys from 2007 to 2014 found that the percentages of non-statin-treated adults with triglyceride levels >150 mg/dL (1.7 mmol/L), >200 mg/dL (2.3 mmol/L), >500 mg/dL (5.7 mmol/L), and >1000 mg/dL (11.3 mmol/L) were 25, 11, 1, and <1 percent, respectively [2]. There were also racial and ethnic differences, with non-Hispanic African Americans having lower fasting TG levels than in non-Hispanic Caucasians and Mexican Americans [3].
Serum TG values >1000 mg/dL (11.3 mmol/L) occur in fewer than 1 in 5000 individuals [4].
And the insurance company will say please take it twice a day and we are not paying for the brand.
It is structurally engineered fatty acid. Studied in NASH and high trigs
Different molecule.
icosabutate vs icosapent
Is the chemical structure the same? If not then it is different molecule.
From my limited google search it is a novel compound.
Vascepa 2.0 is a different compound and would need to go through CVOT trial and the FDA approval. I may be wrong but i doubt this is reasonable strategy
Dosing is the same so that will not work. But based on estimated percentage volumes vs real percentage volume, Amarin can win. I think. Marine label is only a small indication for patients with trigs above 500. I have a large practice and i can count maybe 10 patients with triglycerides above 500 in my entire practice.
I agree.
We can estimate marine label at 5 percent and Reduce label at 95 percent. So if generics volumes are more than 5 percent (let’s say 80 percent) then i think, based on this article, there is a good chance for Amarin to win a case.
Those are below the average salaries.
It is all how much work you want to put in. Know internal medicine guys making over 1.2 million easily
I switched to private practice and make more than when i was working for the hospital.
California, NYC, DC salaries are low
Help me understand. Does amarin have to provide the product that the Canadian partner pays for and on top of it that pay royalties?
So are you telling me making 20 million per year while the partner sells 350 million a year is a good deal? Really? Whoever did this is a moron. Canada is almost US. It is right there.
Who made such bad deal for Canada?
Canada sales to be $350 millions while amarin will get 20 millions the most.
Yes anyone can make OTC but only Amarin can label it for REDUCE-IT
Decrease in stroke, MI and CV death.
The new molecule the vascepa rep mentioned would not work without the new CVOT study.
Nothing wrong
As a physician and prescriber, i know insurances will not approve it. They will ask me to write scripts for 2 separate medications.
Statin plus vascepa will not be approved by insurance. Good luck with that. Not happening.
Fire the reps and use that money to
Advertise like the pillow guy.
Buy Vascepa at your local supermarket, walmart, Costco, Whole Foods or Amazon.
If the pillow guy can do it, Amarin can as well.
That sounds like great idea.
Du said generics won the “skinny label”. Let it be skinny
Why not. It would be sold in higher quantities. Also distribute it through Amazon.
Love the idea. That would slow generics roll out for sure. Sell it to Bayer. Huge European pharma. They can even combine it with Bayer Aspirin (combo pill).
Bayer will sell ton of vascepa in europe and they can do OTC in the US.
Up to 5 percent. Not up to 99 percent. Easily to prove it is more than 5 percent
None of 3 judges read anything. Maybe they skimmed 20 minutes prior to the case.
Aspirin, advil, naproxen all have bleeding risks. Advil and naproxen damage kidneys in millions of patients every day. They also can cause CHF.
Tylenol can damage liver.
Every day patients walk in my clinic with full bag of supplements, mostly pure garbage. Some patients pay more than $200 per month and all they get is an expensive pee. OTC Vascepa would great idea. FDA approved. RTC proved. Put it on amazon as well.
The best hope would be to possible sie insurance companies as they would be the only ones directly infringing on reduce it patents.
OTC Vascepa
Big label with the heart picture:
reduces heart attacks and strokes based on studies
Reduces arterial blockages
Put it in all pharmacies, costco, supermarkets.
$100 a month.
Would be successful IMHO
Few points:
1) Drugs are not allowed to be advertised in Europe
2) Europe population is more than double US population